Psychedelics pushed via EO

President Donald Trump signed an executive order on April 18 directing federal agencies to speed research, review and possible access for psychedelic drugs, including ibogaine, for serious mental illness. (whitehouse.gov) The order tells the Food and Drug Administration to prioritize certain psychedelic drugs that already have Breakthrough Therapy designation, and it tells the Drug Enforcement Administration and FDA to create a pathway for some patients to seek investigational access under the federal Right to Try law. (whitehouse.gov) The White House said more than 14 million U.S. adults have a serious mental illness and about 8 million take prescription medication for those conditions. It also said the Department of Health and Human Services must set aside $50 million through the Advanced Research Projects Agency for Health to match state spending on psychedelic research. (whitehouse.gov) Psychedelic treatment usually means giving a drug during a tightly supervised medical session, then measuring whether symptoms improve over weeks or months. The FDA already has draft guidance for companies studying psychedelics in conditions including psychiatric and substance use disorders. (fda.gov) Ibogaine is a psychoactive compound from an African shrub that has drawn interest for post-traumatic stress disorder, traumatic brain injury and addiction, especially among veterans seeking options outside standard care. CNBC reported Trump signed the order alongside Health and Human Services Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, Joe Rogan and former Navy SEAL Marcus Luttrell. (cnbc.com) The administration’s move lands in a field where no ibogaine product is approved by the FDA. The agency’s drug approvals database is the benchmark list for approved medicines, and ibogaine does not appear there as an approved treatment. (fda.gov) Federal regulators have already shown interest in other psychedelics. The National Center for Complementary and Integrative Health says the FDA granted breakthrough designation to psilocybin-assisted psychotherapy for treatment-resistant depression in 2018 and major depressive disorder in 2019. (nccih.nih.gov) Safety is the central limit on ibogaine’s path. A National Institutes of Health-hosted paper says ibogaine has been linked to deaths tied mainly to dangerous heart-rhythm problems after QT prolongation, and a New England Journal of Medicine case report warned it can cause severe rhythm abnormalities even at doses used in treatment settings. (pmc.ncbi.nlm.nih.gov, (nejm.org)) The Department of Veterans Affairs has already been moving into psychedelic research, but with narrower studies and formal trials. In 2024, VA said it would fund studies on psychedelics for post-traumatic stress disorder and depression, and in 2024 it also announced its first VA-funded study of MDMA-assisted therapy for veterans with PTSD and alcohol use disorder since the 1960s. (news.va.gov, (news.va.gov)) What changes next is not automatic approval but a faster federal push: more trial recruitment, quicker review for qualifying drugs, and earlier planning for rescheduling if a product clears Phase 3 trials and wins FDA approval. The harder question, now shifted onto regulators and researchers, is whether that speed can produce evidence strong enough to satisfy the FDA’s safety and efficacy standard. (whitehouse.gov, (fda.gov)